Physician profile
Ali Nasser
NPI 1457387888
$3,901.78
in general payments reported to CMS, 2019-2025
35 companies · $683 in 2025
The $683 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $564 · 2020: $503 · 2021: $484 · 2022: $327 · 2023: $579 · 2024: $761 · 2025: $683.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,012 · Education: $10.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,012.14 |
| Education | $10.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $512.87 | 2019-2025 | |
| Pfizer INC. | $420.81 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $415.00 | 2021-2025 | Verquvo, Capvaxive |
| Astrazeneca Pharmaceuticals LP | $320.36 | 2019-2024 | Brilinta |
| Philips North America LLC | $228.75 | 2022-2025 | Ecc Solutions, (Cm9) Amb Mon & Diag Und |
| Amgen INC. | $216.62 | 2019-2025 | Repatha, Repatha |
| Novo Nordisk INC | $186.12 | 2019-2021 | |
| Amarin Pharma, INC. | $164.50 | 2019-2020 | |
| Esperion Therapeutics, INC. | $149.62 | 2020-2023 | Nexletol |
| Biotronik INC. | $110.39 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $100.67 | 2020-2025 | Jardiance |
| Edwards Lifesciences Corporation | $96.58 | 2021-2025 | Sapien 3 Ultra Resilia |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $94.86 | 2019-2024 | Lifevest |
| Astellas Pharma US INC | $84.07 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $83.96 | 2020-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $73.33 | 2025 | Dupixent |
| Abbott Laboratories | $73.01 | 2022-2025 | Aveir |
| Kestra Medical Technology Services, INC. | $69.11 | 2024-2025 | Assure Wcd |
| Abiomed | $55.67 | 2023-2025 | Impella |
| Medicomp INC | $52.73 | 2023 | Telepatch Cardiac Monitor |
| Allergan, INC. | $46.17 | 2019 | |
| Impulse Dynamics (USA) INC. | $36.39 | 2024 | Optimizer |
| Bayer Healthcare Pharmaceuticals INC. | $36.05 | 2023-2025 | |
| Baxter Healthcare | $32.57 | 2024-2025 | Hillrom - Cardiac Ambulatory Monitor |
| Boston Scientific Corporation | $32.09 | 2021-2024 | Watchman Flx |
| E.R. Squibb & Sons, L.L.C. | $29.65 | 2021-2023 | Eliquis |
| Recor Medical INC | $25.23 | 2024 | Paradise Renal Denervation System |
| Vifor Pharma, INC. | $24.68 | 2019 | |
| Daiichi Sankyo INC. | $22.65 | 2024 | Injectafer |
| Endo Pharmaceuticals INC. | $22.12 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $21.40 | 2023 | Inpefa |
| Medtronic, INC. | $18.37 | 2021 | |
| Sanofi-Aventis U.S. LLC | $17.22 | 2020 | |
| Eisai INC. | $14.10 | 2020 | |
| Glaxosmithkline, LLC. | $14.06 | 2024 | Shingrix, Arexvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Nasser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.